Therese Aurran

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Journal: EClinicalMedicine
Published: July 30, 2025

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)
Published: June 28, 2025

Improving transparency and empowerment for cancer patients by accessing their full online personal medical records.

Improving transparency and empowerment for cancer patients by accessing their full online personal medical records.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: April 10, 2025

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Journal: Annals of hematology
Published: August 26, 2024

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.

Journal: Nature communications
Published: February 19, 2024

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 10, 2023

Late-Onset Progressive Multifocal Leukoencephalopathy (PML) and Lymphoma in a 65-Year-Old Patient with XIAP Deficiency.

Late-Onset Progressive Multifocal Leukoencephalopathy (PML) and Lymphoma in a 65-Year-Old Patient with XIAP Deficiency.

Journal: Journal of clinical immunology
Published: April 14, 2021

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Journal: Blood advances
Published: November 25, 2020

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.

Journal: Annals of hematology
Published: July 15, 2020

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

Journal: Blood
Published: July 13, 2020

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

Journal: The Lancet. Haematology
Published: April 17, 2019

Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.

Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.

Journal: American journal of hematology
Published: March 16, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026